Cargando…

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with spike protein mutations raises concerns that antibodies elicited by natural infection or vaccination and therapeutic monoclonal antibodies will become less effective. We show that convalescent-pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Takuya, Dcosta, Belinda M., Samanovic, Marie I., Herati, Ramin S., Cornelius, Amber, Zhou, Hao, Vaill, Ada, Kazmierski, Wes, Mulligan, Mark J., Landau, Nathaniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262901/ https://www.ncbi.nlm.nih.gov/pubmed/34060334 http://dx.doi.org/10.1128/mBio.00696-21

Ejemplares similares

High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals
por: Tada, Takuya, et al.
Publicado: (2022)

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
por: Tada, Takuya, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes
por: Hein, Sascha, et al.
Publicado: (2021)

Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
por: Counoupas, Claudio, et al.
Publicado: (2022)

Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent
por: Zhang, Meng, et al.
Publicado: (2022)

Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines
por: Samanovic, Marie I., et al.
Publicado: (2022)

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
por: Kuzmina, Alona, et al.
Publicado: (2021)

Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021)

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021)

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma
por: Salazar, Eric, et al.
Publicado: (2020)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Effect of time and titer in convalescent plasma therapy for COVID-19
por: de Candia, Paola, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
por: Yahalom-Ronen, Yfat, et al.
Publicado: (2022)

The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
por: Fisher, David L., et al.
Publicado: (2021)

Biofilm and planktonic pneumococci demonstrate disparate immunoreactivity to human convalescent sera
por: Sanchez, Carlos J, et al.
Publicado: (2011)

SARS corona virus peptides recognized by antibodies in the sera of convalescent cases
por: Guo, Jian-Ping, et al.
Publicado: (2004)

Development of an ELISA for distinguishing convalescent sera with Mycoplasma hyopneumoniae infection from hyperimmune sera responses to bacterin vaccination in pigs
por: Ding, Honglei, et al.
Publicado: (2021)

Multimodal characterization of antigen-specific CD8(+) T cells across SARS-CoV-2 vaccination and infection
por: Zhang, Bingjie, et al.
Publicado: (2023)

MOUSE-PROTECTIVE TITERS OF SERA OF VOLUNTEERS FOLLOWING INJECTION OF PNEUMOCOCCI OR THEIR TYPE-SPECIFIC POLYSACCHARIDES
por: Walter, Annabel W., et al.
Publicado: (1946)

Multimodal single-cell datasets characterize antigen-specific CD8(+) T cells across SARS-CoV-2 vaccination and infection
por: Zhang, Bingjie, et al.
Publicado: (2023)

NEUTRALIZATION TESTS WITH SERA OF CONVALESCENT OR IMMUNIZED ANIMALS AND THE VIRUSES OF SWINE AND HUMAN INFLUENZA
por: Francis, Thomas, et al.
Publicado: (1936)

Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera
por: Kannenberg, Judith, et al.
Publicado: (2021)

Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong, Yunnan
por: Ma, Yingshuo, et al.
Publicado: (2021)

Inflammation durably imprints memory CD4+ T cells
por: Gray-Gaillard, Sophie L., et al.
Publicado: (2023)

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry
por: He, Yuxian, et al.
Publicado: (2004)

Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays
por: Valdivia, Arantxa, et al.
Publicado: (2021)

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
por: Jangra, Sonia, et al.
Publicado: (2021)

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

Strangles, convalescent Streptococcus equi subspecies equi M antibody titers, and presence of complications
por: Delph, Katherine M., et al.
Publicado: (2018)

Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19
por: Fazeli, Alieh, et al.
Publicado: (2022)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

High Heterogeneity of Virus-Neutralizing and RBD-Binding Activities of COVID-19 Convalescent Sera
por: Astakhova, E. A., et al.
Publicado: (2022)

Evidence for Congenital Zika Virus Infection From Neutralizing Antibody Titers in Maternal Sera, Northeastern Brazil
por: Moreira-Soto, Andres, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n3b9nejeqpa89g9k2njab9dh2j